Sandbox Reserved 1108
From Proteopedia
(Difference between revisions)
(13 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
{{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | {{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
- | == | + | ==4iv6== |
- | + | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | |
- | + | 4iv6 is an enzyme ''Mycobacterium tuberculosis'' which get his structure analyzed by Baugh et al. [https://www.ncbi.nlm.nih.gov/pubmed/25613812] with other enzymes homologue in order to fight ''Mycobacterium tuberculosis'' relative infections. | |
- | + | ||
== Function == | == Function == | ||
+ | 4iv6 functions were not studied and only structural infos are disponible. | ||
+ | Nevertheless we can consider datas from other E.C.1.3.8.1[https://enzyme.expasy.org/EC/1.3.8.1] which came from other organisms. | ||
+ | E.C.1.3.8.1[https://enzyme.expasy.org/EC/1.3.8.1] is communly found in following pathways with various functions: | ||
+ | |||
+ | [[Analine metabolism]]:[https://www.brenda-enzymes.info/pathway_index.php?pathway=alanine%20metabolism&ecno=1.3.8.1] | ||
+ | |||
+ | [[Butanoate metabolism]]:[https://www.genome.jp/kegg-bin/show_pathway?map00650+1.3.8.1] | ||
+ | |||
+ | [[Lipids metabolism]] : [https://www.brenda-enzymes.info/pathway_index.php?pathway=lipid%20metabolism&ecno=1.3.8.1][https://www.genome.jp/kegg-bin/show_pathway?map00071+1.3.8.1] | ||
+ | |||
+ | [[Valine Leucine and isoleucine pathways]]:[https://www.genome.jp/kegg-bin/show_pathway?map00280+1.3.8.1] | ||
+ | |||
+ | |||
==Primary and Secondary structure<ref>http://www.rcsb.org/structure/4IV6</ref>== | ==Primary and Secondary structure<ref>http://www.rcsb.org/structure/4IV6</ref>== | ||
- | Isovaleryl-CoA dehydrogenase is the assembly of '''<scene name='82/829361/2asymunit/1'>two asymmetric units</scene>''' each composed of '''two chains <scene name='82/829361/Chainea_asymunit/2'>A</scene> and <scene name='82/829361/Chaineb_asymunit/1'>B</scene>''' | + | Isovaleryl-CoA dehydrogenase is the assembly of '''<scene name='82/829361/2asymunit/1'>two asymmetric units</scene>''' each composed of '''two chains <scene name='82/829361/Chainea_asymunit/2'>A</scene> and <scene name='82/829361/Chaineb_asymunit/1'>B</scene>'''. Each of the two chains A and B are composed of 388 amino acids. An asymmetric unit is therefore composed of 776 amino acids and has a molecular weight of 86233.70 Da. |
+ | 1% of the unit's amino acid have incomplete sidechains, which means that there are 11 missing residue in the assymetric unit.<ref>https://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4iv6</ref> | ||
The A chain is made up of <scene name='82/829361/Helixalphachaina_asymunit/1'>17 helices</scene> (involving 221 residues) and <scene name='82/829361/Betasheetchaina_asymunit/1'>14 beta-sheets</scene> (61 residues). | The A chain is made up of <scene name='82/829361/Helixalphachaina_asymunit/1'>17 helices</scene> (involving 221 residues) and <scene name='82/829361/Betasheetchaina_asymunit/1'>14 beta-sheets</scene> (61 residues). | ||
Line 14: | Line 27: | ||
==Tertiary structures== | ==Tertiary structures== | ||
- | ==Enzymatic reaction== | + | |
+ | The two chains A and B of the isovaleryl-CoA dehydrogenase are linked by a <scene name='82/829361/Ligand_asymunit/1'>ligand</scene> (Dihydroflavine-Adenine Dinucleotide also known as [https://pubchem.ncbi.nlm.nih.gov/compound/Dihydroflavine-adenine-dinucleotide FADH2] ). | ||
+ | |||
+ | The protein is a tetramer, the surface between the two monomers of a single dimer of an acyl-CoA dehydrogenase contains the FAD binding sites and has extensive bonding interactions. There are 2 active sites in the tetramer, each of these 2 sites contains a FAD molecule and an acyl-CoA substrate binding site. <ref>https://en.wikipedia.org/wiki/Flavin_adenine_dinucleotide</ref> | ||
+ | |||
+ | ==Enzymatic reaction<ref>http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=4iv6</ref><ref>https://www.ebi.ac.uk/intenz/query?cmd=SearchEC&ec=1.3.8.1</ref><ref>https://enzyme.expasy.org/EC/1.3.8.1</ref>== | ||
[[Enzyme accepted name]]: Short-chain acyl-CoA dehydrogenase | [[Enzyme accepted name]]: Short-chain acyl-CoA dehydrogenase | ||
Line 28: | Line 46: | ||
[[Products]]: a short-chain trans-2,3-dehydroacyl-CoA + reduced electron-transfer flavoprotein | [[Products]]: a short-chain trans-2,3-dehydroacyl-CoA + reduced electron-transfer flavoprotein | ||
- | [[Pathways]]: Fatty acid degradation | + | [[Informed Pathways]]: Fatty acid degradation |
[[Other information]]: | [[Other information]]: | ||
- | The enzyme from beef liver can accept acyl-chain lengths from 3 to 8 carbon atoms. From different organism the range can vary so we ignore if | + | The enzyme from beef liver can accept acyl-chain lengths from 3 to 8 carbon atoms. From different organism the range can vary so we ignore if ''Mycobacterium tuberculosis'' gets the same lengths resolution. |
The highest activity reported for beef liver enzyme was for substrates with 4 and 5 carbon acyl-chain lengths. | The highest activity reported for beef liver enzyme was for substrates with 4 and 5 carbon acyl-chain lengths. | ||
Line 40: | Line 58: | ||
4iv6 which belong to ''Mycobacterium tuberculosis'' was studied with other protein homolog. | 4iv6 which belong to ''Mycobacterium tuberculosis'' was studied with other protein homolog. | ||
They were chosen to be studied as potential TB-Drugs target | They were chosen to be studied as potential TB-Drugs target | ||
- | Studies have been made on homolog similarities aimed on their active site because with the knowledges of many homolog active site structure and how they work, we can design a inhibitor of those enzyme which can stop essential reaction and reduce or stop '' | + | Studies have been made on homolog similarities aimed on their active site because with the knowledges of many homolog active site structure and how they work, we can design a inhibitor of those enzyme which can stop essential reaction and reduce or stop ''Mycobacterium tuberculosis'' infection. |
This strategy is called an « Homolog-rescue strategy ». | This strategy is called an « Homolog-rescue strategy ». | ||
This strategy can be generalized for other drug target for other diseases. | This strategy can be generalized for other drug target for other diseases. | ||
- | == Structural highlights == | + | == Structural highlights summary == |
+ | |||
<scene name='82/829361/Biological_unit/1'>Biological unit</scene> | <scene name='82/829361/Biological_unit/1'>Biological unit</scene> | ||
- | <scene name='82/829361/ | + | <scene name='82/829361/2asymunit/1'>Asymmetric units</scene> |
+ | |||
+ | <scene name='82/829361/Betasheetchaina_asymunit/1'>Beta-sheets</scene> | ||
+ | |||
+ | <scene name='82/829361/Helixalphachaina_asymunit/1'>Helices</scene> | ||
+ | |||
+ | <scene name='82/829361/Secondary_structure/1'>Secondary structure</scene> | ||
+ | |||
+ | <scene name='82/829361/Chainea_asymunit/2'>A chain</scene> | ||
- | <scene name='82/829361/ | + | <scene name='82/829361/Chaineb_asymunit/1'>B chain</scene> |
- | <scene name='82/829361/Hydrophobic/1'>Hydrophobic region</scene> | + | <scene name='82/829361/Hydrophobic/1'>Hydrophobic region</scene> |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Current revision
This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115. |
To get started:
More help: Help:Editing |
4iv6
|
References
- ↑ http://www.rcsb.org/structure/4IV6
- ↑ https://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4iv6
- ↑ https://en.wikipedia.org/wiki/Flavin_adenine_dinucleotide
- ↑ http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=4iv6
- ↑ https://www.ebi.ac.uk/intenz/query?cmd=SearchEC&ec=1.3.8.1
- ↑ https://enzyme.expasy.org/EC/1.3.8.1